CK2α as a prognostic factor in invasive ductal carcinomas of the breast: cancer recurrence prognosis by surgical sampling
Breast cancer is the most common cancer in Japanese and Asian women. Although the 5-year survival rate of these patients is relatively high, recurrences and fatalities do occur. The objective of this work was to develop a reliable prognostic indicator to guide therapeutic intervention without waitin...
Gespeichert in:
| Veröffentlicht in: | The lancet oncology 2022-07, Vol.23, p.S25-S25 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S25 |
|---|---|
| container_issue | |
| container_start_page | S25 |
| container_title | The lancet oncology |
| container_volume | 23 |
| creator | Homma, Miwako Kato Hashimoto, Yuko Homma, Yoshimi Nomizu, Tadashi |
| description | Breast cancer is the most common cancer in Japanese and Asian women. Although the 5-year survival rate of these patients is relatively high, recurrences and fatalities do occur. The objective of this work was to develop a reliable prognostic indicator to guide therapeutic intervention without waiting for recurrence or metastasis.
We have previously shown that positive immunohistochemical staining of a protein kinase, CK2α (CSNK2A1), in nucleoli of invasive ductal carcinoma cells is strongly associated with tumour recurrence and poor patient outcomes. For this study, we did an immunohistochemistry investigation of the location of CK2α in the nuclei and nucleoli of formalin-fixed, paraffin-embedded tissue block samples from patients with invasive ductal carcinoma who underwent surgery in 2008–14 but no neoadjuvant chemotherapy at Hoshi General Hospital, Fukushima, Japan. Furthermore, a new study with 59 patients with luminal type breast cancer was done. Patients were followed-up (clinicopathological information and outcomes) for more than 5 years. To characterise CK2α-associated proteins systematically, nuclear and nucleolar extracts were prepared from MCF-7 cells and immunoprecipitated with anti-CK2α antibodies followed by nano-flow liquid chromatography mass spectrometry analysis. We did a Kaplan-Meier analysis to evaluate whether nucleolar CK2 staining might be associated with poor recurrence-free survival. This retrospective study was approved by the Institutional Review Boards of Fukushima Medical University and Hoshi General Hospital.
Samples from 112 patients were included. 105 (94%) of 112 patients with invasive ductal carcinoma had high CK2α expression in nuclei, and 41 (37%) of 112 displayed it predominantly in nucleoli. Clinical and pathological malignancy was strongly correlated with high nuclear and nucleolar CK2α expression. Recurrence-free survival was significantly reduced in patients with positive nucleolar CK2α staining (n=41; median 7·89 years [IQR 4·86–8·86]), comparing with patients with negative nucleolar staining (n=71; median 8·89 years [7·87–9·79]; p |
| doi_str_mv | 10.1016/S1470-2045(22)00424-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2688975463</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1470204522004247</els_id><sourcerecordid>2688975463</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1777-88652de233a56797ba0b9de39cf919ff50d1f0d7768a5635cc492311578f8be33</originalsourceid><addsrcrecordid>eNqFkM1KAzEUhYMoWKuPIATc6GI0ySSTjBuR4h8WXKjrkMkkNaWd1GSm0L6VL-IzmenoWgjkknvOyb0fAKcYXWKEi6tXTDnKCKLsnJALhCihGd8Do_RMM0aF2N_Vg-QQHMU4RwhzjNgIbCfP5PsLqggVXAU_a3xsnYZW6dYH6Jp01iq6tYF1p1u1gFoF7Rq_TA5vYfthYBWMiu116jTaBBiM7kIwqf4LdBFWGxi7MHM6JUS1XC1cMzsGB1Ytojn5vcfg_f7ubfKYTV8enia300xjznkmRMFIbUieK1bwklcKVWVt8lLbEpfWMlRji2rOC5EEOdOaliTHmHFhRWXyfAzOhtw0zmdnYivnvgtN-lKSQoiSM1r0KjaodPAxBmPlKrilChuJkewxyx1m2TOUhMgdZsmT72bwmbTC2pkgo3b99rVLJFpZe_dPwg80koW2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2688975463</pqid></control><display><type>article</type><title>CK2α as a prognostic factor in invasive ductal carcinomas of the breast: cancer recurrence prognosis by surgical sampling</title><source>Elsevier ScienceDirect Journals</source><creator>Homma, Miwako Kato ; Hashimoto, Yuko ; Homma, Yoshimi ; Nomizu, Tadashi</creator><creatorcontrib>Homma, Miwako Kato ; Hashimoto, Yuko ; Homma, Yoshimi ; Nomizu, Tadashi</creatorcontrib><description>Breast cancer is the most common cancer in Japanese and Asian women. Although the 5-year survival rate of these patients is relatively high, recurrences and fatalities do occur. The objective of this work was to develop a reliable prognostic indicator to guide therapeutic intervention without waiting for recurrence or metastasis.
We have previously shown that positive immunohistochemical staining of a protein kinase, CK2α (CSNK2A1), in nucleoli of invasive ductal carcinoma cells is strongly associated with tumour recurrence and poor patient outcomes. For this study, we did an immunohistochemistry investigation of the location of CK2α in the nuclei and nucleoli of formalin-fixed, paraffin-embedded tissue block samples from patients with invasive ductal carcinoma who underwent surgery in 2008–14 but no neoadjuvant chemotherapy at Hoshi General Hospital, Fukushima, Japan. Furthermore, a new study with 59 patients with luminal type breast cancer was done. Patients were followed-up (clinicopathological information and outcomes) for more than 5 years. To characterise CK2α-associated proteins systematically, nuclear and nucleolar extracts were prepared from MCF-7 cells and immunoprecipitated with anti-CK2α antibodies followed by nano-flow liquid chromatography mass spectrometry analysis. We did a Kaplan-Meier analysis to evaluate whether nucleolar CK2 staining might be associated with poor recurrence-free survival. This retrospective study was approved by the Institutional Review Boards of Fukushima Medical University and Hoshi General Hospital.
Samples from 112 patients were included. 105 (94%) of 112 patients with invasive ductal carcinoma had high CK2α expression in nuclei, and 41 (37%) of 112 displayed it predominantly in nucleoli. Clinical and pathological malignancy was strongly correlated with high nuclear and nucleolar CK2α expression. Recurrence-free survival was significantly reduced in patients with positive nucleolar CK2α staining (n=41; median 7·89 years [IQR 4·86–8·86]), comparing with patients with negative nucleolar staining (n=71; median 8·89 years [7·87–9·79]; p<0·0001). Kaplan-Meier analysis showed a decrease of approximately 50% in recurrence-free survival in patients with nucleolar CK2α-positive stain in the triple-negative breast cancer (p=0·0069) and post-operative stage 3 (p=0·0073) groups. By contrast, no patients who relapsed or died in the triple-negative breast cancer group had negative staining for nucleolar CK2α. Evaluation of nucleolar CK2α can be considered as an independent prognostic factor because it reached significance in multivariate analysis (hazard ratio [HR] 5·26 [95% CI 1·35–20·55]; p=0·017). In addition, the HR of nucleolar CK2α-positive staining was less affected by adjustments in Cox proportional multivariate analysis. Cluster analysis showed that nucleolar CK2α-positive staining contributed more than any other clinicopathological factor to predicting the variation in the future length of survival. Analysis with luminal type breast cancer (n=59), in which the risk of recurrence is generally low and which is treated postoperatively with hormone therapy alone, showed that cancer recurrence and poor patient outcomes strongly associate with nucleolar CK2α-positive stain (n=7; p=0·037) by Kaplan-Meier analysis. In this case, nucleolar CK2α is considered a sole independent prognostic factor (HR 2·11 [95% CI 0·27–3·69]; p=0·0087). Evaluation of this method in other solid tumours is ongoing.
Our results suggest that the evaluation of nucleolar CK2α-positive staining might be a new and independent prognostic factor that can improve treatment efficacy and patient quality of life after surgical resection of the tumour. The application of this analysis could contribute to early treatment strategy decisions and to companion diagnostics. The protein interactome of nuclear CK2 complexes showed CK2α's role in protein synthesis and RNA post-transcriptional modification. Specifically, a more detailed evaluation of CK2α function in nucleolar events in malignant cells might lead to the development of novel, more accurately targeted anti-cancer therapeutics. In conclusion, evaluating nucleolar CK2α staining in combination with other clinicopathological indicators might allow for a more accurate prediction of future recurrence or metastasis, which cannot be accomplished by current methods.
Japan Agency for Medical Research and Development (grant number 20lm0203006j0004).</description><identifier>ISSN: 1470-2045</identifier><identifier>EISSN: 1474-5488</identifier><identifier>DOI: 10.1016/S1470-2045(22)00424-7</identifier><language>eng</language><publisher>London: Elsevier Ltd</publisher><subject>Breast cancer ; Breast carcinoma ; Cancer therapies ; Chemotherapy ; Clinical outcomes ; Immunohistochemistry ; Invasiveness ; Kinases ; Liquid chromatography ; Malignancy ; Mass spectroscopy ; Medical prognosis ; Medical research ; Metastases ; Metastasis ; Multivariate analysis ; Nucleoli ; Paraffin ; Patients ; Post-transcription ; Protein biosynthesis ; Protein kinase ; Proteins ; Quality of life ; RNA modification ; Solid tumors ; Stains & staining</subject><ispartof>The lancet oncology, 2022-07, Vol.23, p.S25-S25</ispartof><rights>2022 Elsevier Ltd</rights><rights>2022. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1470204522004247$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids></links><search><creatorcontrib>Homma, Miwako Kato</creatorcontrib><creatorcontrib>Hashimoto, Yuko</creatorcontrib><creatorcontrib>Homma, Yoshimi</creatorcontrib><creatorcontrib>Nomizu, Tadashi</creatorcontrib><title>CK2α as a prognostic factor in invasive ductal carcinomas of the breast: cancer recurrence prognosis by surgical sampling</title><title>The lancet oncology</title><description>Breast cancer is the most common cancer in Japanese and Asian women. Although the 5-year survival rate of these patients is relatively high, recurrences and fatalities do occur. The objective of this work was to develop a reliable prognostic indicator to guide therapeutic intervention without waiting for recurrence or metastasis.
We have previously shown that positive immunohistochemical staining of a protein kinase, CK2α (CSNK2A1), in nucleoli of invasive ductal carcinoma cells is strongly associated with tumour recurrence and poor patient outcomes. For this study, we did an immunohistochemistry investigation of the location of CK2α in the nuclei and nucleoli of formalin-fixed, paraffin-embedded tissue block samples from patients with invasive ductal carcinoma who underwent surgery in 2008–14 but no neoadjuvant chemotherapy at Hoshi General Hospital, Fukushima, Japan. Furthermore, a new study with 59 patients with luminal type breast cancer was done. Patients were followed-up (clinicopathological information and outcomes) for more than 5 years. To characterise CK2α-associated proteins systematically, nuclear and nucleolar extracts were prepared from MCF-7 cells and immunoprecipitated with anti-CK2α antibodies followed by nano-flow liquid chromatography mass spectrometry analysis. We did a Kaplan-Meier analysis to evaluate whether nucleolar CK2 staining might be associated with poor recurrence-free survival. This retrospective study was approved by the Institutional Review Boards of Fukushima Medical University and Hoshi General Hospital.
Samples from 112 patients were included. 105 (94%) of 112 patients with invasive ductal carcinoma had high CK2α expression in nuclei, and 41 (37%) of 112 displayed it predominantly in nucleoli. Clinical and pathological malignancy was strongly correlated with high nuclear and nucleolar CK2α expression. Recurrence-free survival was significantly reduced in patients with positive nucleolar CK2α staining (n=41; median 7·89 years [IQR 4·86–8·86]), comparing with patients with negative nucleolar staining (n=71; median 8·89 years [7·87–9·79]; p<0·0001). Kaplan-Meier analysis showed a decrease of approximately 50% in recurrence-free survival in patients with nucleolar CK2α-positive stain in the triple-negative breast cancer (p=0·0069) and post-operative stage 3 (p=0·0073) groups. By contrast, no patients who relapsed or died in the triple-negative breast cancer group had negative staining for nucleolar CK2α. Evaluation of nucleolar CK2α can be considered as an independent prognostic factor because it reached significance in multivariate analysis (hazard ratio [HR] 5·26 [95% CI 1·35–20·55]; p=0·017). In addition, the HR of nucleolar CK2α-positive staining was less affected by adjustments in Cox proportional multivariate analysis. Cluster analysis showed that nucleolar CK2α-positive staining contributed more than any other clinicopathological factor to predicting the variation in the future length of survival. Analysis with luminal type breast cancer (n=59), in which the risk of recurrence is generally low and which is treated postoperatively with hormone therapy alone, showed that cancer recurrence and poor patient outcomes strongly associate with nucleolar CK2α-positive stain (n=7; p=0·037) by Kaplan-Meier analysis. In this case, nucleolar CK2α is considered a sole independent prognostic factor (HR 2·11 [95% CI 0·27–3·69]; p=0·0087). Evaluation of this method in other solid tumours is ongoing.
Our results suggest that the evaluation of nucleolar CK2α-positive staining might be a new and independent prognostic factor that can improve treatment efficacy and patient quality of life after surgical resection of the tumour. The application of this analysis could contribute to early treatment strategy decisions and to companion diagnostics. The protein interactome of nuclear CK2 complexes showed CK2α's role in protein synthesis and RNA post-transcriptional modification. Specifically, a more detailed evaluation of CK2α function in nucleolar events in malignant cells might lead to the development of novel, more accurately targeted anti-cancer therapeutics. In conclusion, evaluating nucleolar CK2α staining in combination with other clinicopathological indicators might allow for a more accurate prediction of future recurrence or metastasis, which cannot be accomplished by current methods.
Japan Agency for Medical Research and Development (grant number 20lm0203006j0004).</description><subject>Breast cancer</subject><subject>Breast carcinoma</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Clinical outcomes</subject><subject>Immunohistochemistry</subject><subject>Invasiveness</subject><subject>Kinases</subject><subject>Liquid chromatography</subject><subject>Malignancy</subject><subject>Mass spectroscopy</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Multivariate analysis</subject><subject>Nucleoli</subject><subject>Paraffin</subject><subject>Patients</subject><subject>Post-transcription</subject><subject>Protein biosynthesis</subject><subject>Protein kinase</subject><subject>Proteins</subject><subject>Quality of life</subject><subject>RNA modification</subject><subject>Solid tumors</subject><subject>Stains & staining</subject><issn>1470-2045</issn><issn>1474-5488</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqFkM1KAzEUhYMoWKuPIATc6GI0ySSTjBuR4h8WXKjrkMkkNaWd1GSm0L6VL-IzmenoWgjkknvOyb0fAKcYXWKEi6tXTDnKCKLsnJALhCihGd8Do_RMM0aF2N_Vg-QQHMU4RwhzjNgIbCfP5PsLqggVXAU_a3xsnYZW6dYH6Jp01iq6tYF1p1u1gFoF7Rq_TA5vYfthYBWMiu116jTaBBiM7kIwqf4LdBFWGxi7MHM6JUS1XC1cMzsGB1Ytojn5vcfg_f7ubfKYTV8enia300xjznkmRMFIbUieK1bwklcKVWVt8lLbEpfWMlRji2rOC5EEOdOaliTHmHFhRWXyfAzOhtw0zmdnYivnvgtN-lKSQoiSM1r0KjaodPAxBmPlKrilChuJkewxyx1m2TOUhMgdZsmT72bwmbTC2pkgo3b99rVLJFpZe_dPwg80koW2</recordid><startdate>202207</startdate><enddate>202207</enddate><creator>Homma, Miwako Kato</creator><creator>Hashimoto, Yuko</creator><creator>Homma, Yoshimi</creator><creator>Nomizu, Tadashi</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>202207</creationdate><title>CK2α as a prognostic factor in invasive ductal carcinomas of the breast: cancer recurrence prognosis by surgical sampling</title><author>Homma, Miwako Kato ; Hashimoto, Yuko ; Homma, Yoshimi ; Nomizu, Tadashi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1777-88652de233a56797ba0b9de39cf919ff50d1f0d7768a5635cc492311578f8be33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Breast cancer</topic><topic>Breast carcinoma</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Clinical outcomes</topic><topic>Immunohistochemistry</topic><topic>Invasiveness</topic><topic>Kinases</topic><topic>Liquid chromatography</topic><topic>Malignancy</topic><topic>Mass spectroscopy</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Multivariate analysis</topic><topic>Nucleoli</topic><topic>Paraffin</topic><topic>Patients</topic><topic>Post-transcription</topic><topic>Protein biosynthesis</topic><topic>Protein kinase</topic><topic>Proteins</topic><topic>Quality of life</topic><topic>RNA modification</topic><topic>Solid tumors</topic><topic>Stains & staining</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Homma, Miwako Kato</creatorcontrib><creatorcontrib>Hashimoto, Yuko</creatorcontrib><creatorcontrib>Homma, Yoshimi</creatorcontrib><creatorcontrib>Nomizu, Tadashi</creatorcontrib><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>The lancet oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Homma, Miwako Kato</au><au>Hashimoto, Yuko</au><au>Homma, Yoshimi</au><au>Nomizu, Tadashi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CK2α as a prognostic factor in invasive ductal carcinomas of the breast: cancer recurrence prognosis by surgical sampling</atitle><jtitle>The lancet oncology</jtitle><date>2022-07</date><risdate>2022</risdate><volume>23</volume><spage>S25</spage><epage>S25</epage><pages>S25-S25</pages><issn>1470-2045</issn><eissn>1474-5488</eissn><abstract>Breast cancer is the most common cancer in Japanese and Asian women. Although the 5-year survival rate of these patients is relatively high, recurrences and fatalities do occur. The objective of this work was to develop a reliable prognostic indicator to guide therapeutic intervention without waiting for recurrence or metastasis.
We have previously shown that positive immunohistochemical staining of a protein kinase, CK2α (CSNK2A1), in nucleoli of invasive ductal carcinoma cells is strongly associated with tumour recurrence and poor patient outcomes. For this study, we did an immunohistochemistry investigation of the location of CK2α in the nuclei and nucleoli of formalin-fixed, paraffin-embedded tissue block samples from patients with invasive ductal carcinoma who underwent surgery in 2008–14 but no neoadjuvant chemotherapy at Hoshi General Hospital, Fukushima, Japan. Furthermore, a new study with 59 patients with luminal type breast cancer was done. Patients were followed-up (clinicopathological information and outcomes) for more than 5 years. To characterise CK2α-associated proteins systematically, nuclear and nucleolar extracts were prepared from MCF-7 cells and immunoprecipitated with anti-CK2α antibodies followed by nano-flow liquid chromatography mass spectrometry analysis. We did a Kaplan-Meier analysis to evaluate whether nucleolar CK2 staining might be associated with poor recurrence-free survival. This retrospective study was approved by the Institutional Review Boards of Fukushima Medical University and Hoshi General Hospital.
Samples from 112 patients were included. 105 (94%) of 112 patients with invasive ductal carcinoma had high CK2α expression in nuclei, and 41 (37%) of 112 displayed it predominantly in nucleoli. Clinical and pathological malignancy was strongly correlated with high nuclear and nucleolar CK2α expression. Recurrence-free survival was significantly reduced in patients with positive nucleolar CK2α staining (n=41; median 7·89 years [IQR 4·86–8·86]), comparing with patients with negative nucleolar staining (n=71; median 8·89 years [7·87–9·79]; p<0·0001). Kaplan-Meier analysis showed a decrease of approximately 50% in recurrence-free survival in patients with nucleolar CK2α-positive stain in the triple-negative breast cancer (p=0·0069) and post-operative stage 3 (p=0·0073) groups. By contrast, no patients who relapsed or died in the triple-negative breast cancer group had negative staining for nucleolar CK2α. Evaluation of nucleolar CK2α can be considered as an independent prognostic factor because it reached significance in multivariate analysis (hazard ratio [HR] 5·26 [95% CI 1·35–20·55]; p=0·017). In addition, the HR of nucleolar CK2α-positive staining was less affected by adjustments in Cox proportional multivariate analysis. Cluster analysis showed that nucleolar CK2α-positive staining contributed more than any other clinicopathological factor to predicting the variation in the future length of survival. Analysis with luminal type breast cancer (n=59), in which the risk of recurrence is generally low and which is treated postoperatively with hormone therapy alone, showed that cancer recurrence and poor patient outcomes strongly associate with nucleolar CK2α-positive stain (n=7; p=0·037) by Kaplan-Meier analysis. In this case, nucleolar CK2α is considered a sole independent prognostic factor (HR 2·11 [95% CI 0·27–3·69]; p=0·0087). Evaluation of this method in other solid tumours is ongoing.
Our results suggest that the evaluation of nucleolar CK2α-positive staining might be a new and independent prognostic factor that can improve treatment efficacy and patient quality of life after surgical resection of the tumour. The application of this analysis could contribute to early treatment strategy decisions and to companion diagnostics. The protein interactome of nuclear CK2 complexes showed CK2α's role in protein synthesis and RNA post-transcriptional modification. Specifically, a more detailed evaluation of CK2α function in nucleolar events in malignant cells might lead to the development of novel, more accurately targeted anti-cancer therapeutics. In conclusion, evaluating nucleolar CK2α staining in combination with other clinicopathological indicators might allow for a more accurate prediction of future recurrence or metastasis, which cannot be accomplished by current methods.
Japan Agency for Medical Research and Development (grant number 20lm0203006j0004).</abstract><cop>London</cop><pub>Elsevier Ltd</pub><doi>10.1016/S1470-2045(22)00424-7</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1470-2045 |
| ispartof | The lancet oncology, 2022-07, Vol.23, p.S25-S25 |
| issn | 1470-2045 1474-5488 |
| language | eng |
| recordid | cdi_proquest_journals_2688975463 |
| source | Elsevier ScienceDirect Journals |
| subjects | Breast cancer Breast carcinoma Cancer therapies Chemotherapy Clinical outcomes Immunohistochemistry Invasiveness Kinases Liquid chromatography Malignancy Mass spectroscopy Medical prognosis Medical research Metastases Metastasis Multivariate analysis Nucleoli Paraffin Patients Post-transcription Protein biosynthesis Protein kinase Proteins Quality of life RNA modification Solid tumors Stains & staining |
| title | CK2α as a prognostic factor in invasive ductal carcinomas of the breast: cancer recurrence prognosis by surgical sampling |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T12%3A29%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CK2%CE%B1%20as%20a%20prognostic%20factor%20in%20invasive%20ductal%20carcinomas%20of%20the%20breast:%20cancer%20recurrence%20prognosis%20by%20surgical%20sampling&rft.jtitle=The%20lancet%20oncology&rft.au=Homma,%20Miwako%20Kato&rft.date=2022-07&rft.volume=23&rft.spage=S25&rft.epage=S25&rft.pages=S25-S25&rft.issn=1470-2045&rft.eissn=1474-5488&rft_id=info:doi/10.1016/S1470-2045(22)00424-7&rft_dat=%3Cproquest_cross%3E2688975463%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2688975463&rft_id=info:pmid/&rft_els_id=S1470204522004247&rfr_iscdi=true |